Osteogenesis imperfecta in adult twins responded to treatment with pamidronate [Osteogenezis i?mperfektalı erişkin i?kizlerin pamidronat tedavisine olumlu cevabı]

Basit Öğe Kaydı
dc.contributor.authorÖztürk M.
dc.contributor.authorÇakir M.
dc.date.accessioned2020-03-26T18:22:04Z
dc.date.available2020-03-26T18:22:04Z
dc.date.issued2011
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractBisphosphonates are strong inhibitors of bone resorption and are used in the treatment of osteoporosis. Bisphosphonates are known to be effective in prevention of fractures, improvement of bone mineral density as well as in relieving bone pain in osteogenesis imperfecta (OI) patients. Recent studies have shown that especially intravenous pamidronate may be more effective when given in childhood and adolescence. This effect was also shown in adult OI patients in some clinical trials. 22-year-old twin brothers known to have OI were admitted to our endocrinology and metabolism outpatient clinic. On medical history, OI was diagnosed at the age of three and for the last eight years, they were not able to walk and were using wheelchairs. On physical examination, blue sclerae and dentinogenesis imperfecta were detected in both patients. According to the expanded Sillence classification of OI, the clinical findings were consistent with type IV OI. Intravenous pamidronate treatment was given three times at four-month intervals, according to Montreal protocol. During this period, the patients were also doing isometric exercises and were on physical therapy, diet, and bioresonance therapy. At the end of one year, bone pain regressed significantly in both patients and they were able to walk independently. These outcomes demonstrate that in selected adult OI patients, intravenous pamidronate treatment may be beneficial in preventing bone fractures and relieving pain.en_US
dc.identifier.endpage43en_US
dc.identifier.issn1301-2193en_US
dc.identifier.issue2en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.startpage39en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12395/27118
dc.identifier.volume15en_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherTurkiye Kliniklerien_US
dc.relation.ispartofTurkish Journal of Endocrinology and Metabolismen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjectAdulten_US
dc.subjectOsteogenesis imperfectaen_US
dc.subjectPamidronaten_US
dc.titleOsteogenesis imperfecta in adult twins responded to treatment with pamidronate [Osteogenezis i?mperfektalı erişkin i?kizlerin pamidronat tedavisine olumlu cevabı]en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu